| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut
Requests for reprints: Yung-Chi Cheng, Department of Pharmacology, Yale University School of Medicine, SHM B226, P.O. Box 208066, New Haven, CT 06520-8066. Phone: 203-785-7119; Fax: 203-785-7129; E-mail: yccheng{at}yale.edu.
Poly(ADP-ribose) polymerase-1 (PARP-1) is known to have an important role in camptothecin sensitivity and interacts with topoisomerase I. In the present study, the impact of PARP-1 on the topoisomerase I-DNA complex stabilized by camptothecin was assessed. It was shown that NH2 terminustruncated topoisomerase I (amino acids 201-765) showed at least 4-fold less sensitivity to camptothecin than full-length topoisomerase I in the oligonucleotide religation assay. PARP-1 could prevent the action of camptothecin on the religation activity of full-length topoisomerase I, which is linked to DNA in a stoichiometrical manner. However, the religation activity of NH2 terminustruncated topoisomerase I, which is linked to DNA, could not be enhanced by PARP-1 in the presence of camptothecin. Both full-length and NH2 terminustruncated topoisomerase I interact with PARP-1. This data suggests that PARP-1 destabilizes the topoisomerase I-camptothecin-DNA complex with the participation of the NH2-terminal domain of topoisomerase I. Poly(ADP-ribosyl)ation of topoisomerase I by PARP-1 in the presence its substrate, NAD, could also promote the religation activity of full-length topoisomerase I as well as NH2 terminustruncated topoisomerase I. PARP-1 inhibitors (3-aminobenzamide, PJ34) could inhibit this process. Therefore, PARP-1 could facilitate the religation activity of topoisomerase I by itself through topoisomerase I-PARP-1 interaction (PARP-1 action) or by the formation of poly(ADP-ribosyl)ation of topoisomerase I (PARP-1/NAD action). This study also implies that PARP-1 and PARP-1/NAD actions need to be highly regulated by cellular factors for camptothecin to exert its cytotoxicity inside the cells. We propose ATP to be one of the important regulatory factors.
This article has been cited by other articles:
![]() |
O. Sordet, A. Goldman, C. Redon, S. Solier, V. A. Rao, and Y. Pommier Topoisomerase I Requirement for Death Receptor-induced Apoptotic Nuclear Fission J. Biol. Chem., August 22, 2008; 283(34): 23200 - 23208. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Hackbarth, M. Galvez-Peralta, N. T. Dai, D. A. Loegering, K. L. Peterson, X. W. Meng, L. M. Karnitz, and S. H. Kaufmann Mitotic Phosphorylation Stimulates DNA Relaxation Activity of Human Topoisomerase I J. Biol. Chem., June 13, 2008; 283(24): 16711 - 16722. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Y. Park, C.-H. Leung, and Y.-C. Cheng ATP Modulates Poly(ADP-Ribose) Polymerase-1-Facilitated Topoisomerase I-Linked DNA Religation in the Presence of Camptothecin Mol. Pharmacol., June 1, 2008; 73(6): 1829 - 1837. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Baumann, G. S. Boehden, A. Burkle, and L. Wiesmuller Poly(ADP-RIBOSE) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by P53 Nucleic Acids Res., February 9, 2006; 34(3): 1036 - 1049. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |